Statement of Cash Flows (USD $)	6 Months Ended		101 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
Cash Flows From Operating Activities
Net income (loss)	$ (209,618)	$ 578,672	$ (2,776,882)
Items to reconcile net loss to net cash used in operating activities:
Contributions to capital by related parties - expenses	0	0	58,799
Contributions to capital by related party - forgiveness of debt	0	0	38,950
Common shares issued for services	0	0	30
Stock based compensation	0	132,138	346,050
(Increase) decrease in prepaid expenses and deposits	1,489	2,755	(21,146)
Increase in accounts payable and accrued liabilities, related party	51,672	0	51,672
Increase (decrease) in accounts payable and accrued liabilities	(2,603)	6,230	226,506
Net cash provided by (used in) continuing operations	(159,060)	719,795	(2,076,021)
Net cash provided by (used in) discontinued operations	53,590	(912,763)	(148,830)
Net cash used in operating activities	(105,470)	(192,968)	(2,224,851)
Cash Flows From Investing Activities
Acquisition of SlickX and Flawsome	(50,000)	0	(50,000)
Capitalized website and website development costs	(100,600)	0	(100,600)
Net cash used in continuing investing activities	(150,600)	0	(150,600)
Net cash used in discontinued investing activities	0	0	(53,135)
Net cash used in investing activities	(150,600)	0	(203,735)
Cash Flows From Financing Activities
Proceeds from issuance of promissory notes	0	0	705,000
Principal payments on promissory notes	(200,000)	0	(200,000)
Common shares returned to treasury	0	0	(5,000)
Proceeds from issuance of common stock	0	0	1,985,000
Cash provided by (used in) financing activities	(200,000)	0	2,485,000
Increase (decrease) in cash and cash equivalents	(456,070)	(192,968)	56,414
Cash and cash equivalents, beginning of period	512,484	258,140	0
Cash and cash equivalents, end of period	56,414	65,172	56,414
Noncash investing activity
Apricus Biosciences, Inc. common stock received in consideration for termination of merger agreement	$ 0	$ 0	$ 1,000,000